The U.s. Colorectal Cancer Screening Market Driven By Rising Awareness Among Population

By Author: Ben
Total Articles: 165
Comment this article

The U.S. colorectal cancer screening market consists of diagnostic tests that helps in early detection of colorectal cancer. These screening tests include stool-based tests such as Guaiac-based fecal occult blood test (gFOBT), immunochemical fecal occult blood test (iFOBT) and fecal immunochemical test (FIT). It also includes endoscopic tests such as flexible sigmoidoscopy and colonoscopy. Colonoscopy is considered as gold standard for colorectal cancer screening as it allows examination of the entire colon and rectum. The procedure helps in detection and removal of polyps that may develop into cancer which significantly reduces the chances of colorectal cancer.

The Global U.S. Colorectal Cancer Screening Market Size is estimated to be valued at US$ 5,952.2 Mn in 2024 and is expected to exhibit a CAGR of 7.5% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the U.S. colorectal cancer screening market are Polymedco Inc., Eiken Chemical Co. Ltd., Sysmex Corporation, Quidel Corporation, Novigenix SA and Among Others. The key players are involved in development and commercialization ...
... of advanced screening tests to detect colorectal cancer at an early stage. For instance, in July 2021, Novigenix SA launched its innovative blood test, Nightingale, for screening asymptomatic average-risk individuals for colorectal cancer.

The growing demand for non-invasive and easy to use screening tests is expected to drive the market growth during the forecast period. The non-invasive blood and stool based tests help in increasing the screening rates as they are more convenient and have better patient compliance compared to colonoscopy.

The increasing awareness regarding routine screening through various government initiatives is leading to the global expansion of the U.S colorectal cancer screening market. The various programs aimed at increasing public awareness about risks of colorectal cancer and benefits of screening are encouraging more people to go for timely screening.

Market Drivers

The rising incidence of colorectal cancer in the U.S. is a major market driver. It is estimated that around 149,500 new cases of colorectal cancer are diagnosed and around 52,980 deaths occur annually in the U.S. The growing risks of cancer due to changing lifestyle habits and diet is contributing to the increase in number of cases. This is prompting more people to go for regular screening tests which is fueling the growth of the market.

Impact of geopolitical situation on U.S. colorectal cancer screening market growth and future strategies

The U.S. colorectal cancer screening market is facing many geopolitical challenges which can impact its growth in the coming years. With rising political instability and tensions between certain countries, international trade and cooperation is being hampered. This can affect the import and export of crucial medical equipment and technologies used for cancer screening. The market is also witnessing supply chain disruptions due to lockdowns and shutdowns caused by the COVID-19 pandemic across various regions. This has led to delays in production and shortages of resources. To cope with such challenges, companies must diversify their supplier networks and focus on establishing more local manufacturing units. They should also invest in developing screening solutions using indigenous technologies to improve self-reliance. Partnerships between private labs and public healthcare systems need to be strengthened to ensure better accessibility of screening facilities across rural areas. Telemedicine can be leveraged more to remotely monitor high-risk patients and facilitate virtual consultations with oncologists. Overall, the market needs to prioritize building flexibility, redundancy and local capacity to minimize dependence on global trade flows. This will help sustain its long-term growth trajectory despite adverse geopolitical conditions.

Geographical regions with high concentration of U.S. colorectal cancer screening market value

The U.S. colorectal cancer screening market observes maximum value concentration in the Western and Midwestern regions of the country. States like California, Texas, Florida and New York have among the highest prevalence of colorectal cancer cases as well as number of screening centers, labs and hospitals. This is owing to their large population base and higher healthcare expenditures. For instance, California alone accounts for over 15% of the total market value currently due to presence of advanced medical facilities in cities like Los Angeles and San Francisco. Other populated and economically developed regions within the Midwest and West Coast also contribute significantly, driven by growing health awareness and expanded insurance coverage. Hence, these geographical territories will continue dominating the market in terms of revenue generation in the forthcoming years.

Fastest growing region for the U.S. colorectal cancer screening market

The Southern region of the United States is expected to emerge as the fastest growing geographical segment of the colorectal cancer screening market through 2031. States under this belt like Texas, Florida, North Carolina, Georgia and Virginia are witnessing rapid economic as well as demographic transitions. Awareness initiatives by government bodies and non-profit cancer societies have made important strides in educating at-risk populations regarding early detection benefits. Additionally, improving accessibility of Medicaid programs and targeted screening subsidies are enabling higher participation rates from rural communities. As healthcare infrastructure strengthens across smaller cities and towns, the Southern market will experience stronger CAGRs compared to mature regions. Its growth momentum will be further accelerated by constant development of advanced diagnostic technologies and tailored screening solutions.

What Are The Key Data Covered In This U.S. Colorectal Cancer Screening Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the U.S. Colorectal Cancer Screening's growth between 2024 and 2031.

:- Accurate calculation of the size of the U.S. Colorectal Cancer Screening and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- U.S. Colorectal Cancer Screening Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of U.S. Colorectal Cancer Screening vendors

FAQ’s

Q.1 What are the main factors influencing the U.S. Colorectal Cancer Screening?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top U.S. Colorectal Cancer Screening companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the U.S. Colorectal Cancer Screening’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

Get more insights on this topic: https://heyjinni.com/read-blog/94495